Bicarbonate

Bicarbonate

SCHEMBL3262534

Nc1nc2cccc(-c3cccc(C(F)(F)F)c3)n2n1.O=C(O)O.O=C(O)O

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 3/20 0.62
JAK2 O60674 1/20 0.58
DYRK1A Q13627 4/20 0.51
DYRK2 Q92630 4/20 0.51
EGLN2 Q96KS0 1/20 0.51
JAK1 P23458 2/20 0.48
KDM4E B2RXH2 1/20 0.47
CCNA2 P20248 3/20 0.47
CDK2 P24941 3/20 0.47
CDK5 Q00535 3/20 0.47
CDK5R1 Q15078 3/20 0.47
DYRK1B Q9Y463 3/20 0.47
ADORA2A P29274 2/20 0.45
ADORA1 P30542 2/20 0.45
LRRK2 Q5S007 1/20 0.45
DYRK3 O43781 2/20 0.45
CCNT1 O60563 2/20 0.45
CDK9 P50750 2/20 0.45
THRB P10828 1/20 0.43
KMO O15229 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2144054 0.78 NUDT1 (1.00) NUDT1JAK2DYRK1AEGLN2JAK1
SCHEMBL3087585 0.77 NUDT1 (0.69) NUDT1JAK2EGLN2JAK1KDM4E
SCHEMBL3104923 0.76 NUDT1 (0.59) NUDT1DYRK1AEGLN2JAK1
SCHEMBL10594428 0.76 PIM1 (0.46) NUDT1JAK2DYRK1ADYRK2KDM4E
SCHEMBL3214727 0.76 JAK2 (0.62) JAK2DYRK1ADYRK2CCNA2CDK2
SCHEMBL3205602 0.74 JAK2 (0.60) JAK2JAK1KDM4E
SCHEMBL3104872 0.74 NUDT1 (0.69) NUDT1JAK2DYRK1ADYRK2EGLN2
SCHEMBL13031278 0.74 JAK2 (1.00) JAK2JAK1
SCHEMBL3264207 0.73 NUDT1 (0.72) NUDT1JAK2EGLN2JAK1KDM4E
SCHEMBL3215698 0.73 NUDT1 (0.67) NUDT1JAK2EGLN2JAK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160333011-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2016-11-17 US disclosed
US-9434732-B2 Triazolopyridine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2016-09-06 US disclosed
US-8609687-B2 Triazolopyridine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2013-12-17 US disclosed
US-20120225855-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS ZHU BING-YAN (US) 2012-09-06 US disclosed
US-20100048557-A1 Triazolopyridine JAK Inhibitor Compounds and Methods GENENTECH, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048557-A1 Triazolopyridine JAK Inhibitor Compounds and Methods JAK2, JAK1, JAK3 NUDT1 3080/4885JAK2 1/4885DYRK1A 16/4885
US-20160333011-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK1, JAK2, JAK3 NUDT1 2613/4885JAK2 2/4885DYRK1A 64/4885
US-20120225855-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 NUDT1 3080/4885JAK2 1/4885DYRK1A 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.